The Manufacturers Life Insurance Company Has $639,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

The Manufacturers Life Insurance Company boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 140.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,356 shares of the company’s stock after buying an additional 23,550 shares during the period. The Manufacturers Life Insurance Company’s holdings in Keros Therapeutics were worth $639,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of KROS. MetLife Investment Management LLC increased its stake in Keros Therapeutics by 6.0% in the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company’s stock valued at $286,000 after purchasing an additional 1,027 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after acquiring an additional 1,100 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after acquiring an additional 1,372 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Keros Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company’s stock worth $1,549,000 after acquiring an additional 2,462 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 22.90% of the company’s stock.

Analysts Set New Price Targets

KROS has been the subject of several recent research reports. Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Wedbush reissued a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Oppenheimer decreased their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Moderate Buy” and an average price target of $37.00.

Keros Therapeutics Stock Performance

Shares of KROS stock opened at $14.03 on Friday. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The company has a 50-day simple moving average of $12.38 and a two-hundred day simple moving average of $23.44. The company has a market capitalization of $569.83 million, a price-to-earnings ratio of -2.69 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same period in the prior year, the firm posted ($1.21) EPS. On average, sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.